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Despite the widespread adoption of multimo-dality therapy, the diagnosis of glioblastoma multiforme (GBM) continues to carry a dis-
mal prognosis with a grave overall survival estimate set 
at 9 to 12 months.1-3 Surgery followed by radiotherapy 
was considered the standard of care.3 Temozolomide 
(TMZ) administered in addition to adjuvant radio-
therapy (RT) has been shown to significantly prolong 
overall survival.4 Currently, TMZ concurrent with RT 
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BACKGROUND AND OBJECTIVES: the management of glioblastoma multiforme (GBm) in developing coun-
tries is hindered by the paucity of clear protocols due in part to growing economic constraints and the lack 
of availability of expensive chemotherapeutic agents. We evaluated the deliverable treatment protocols and 
achievable outcomes for patients with GBm in a low-income country prior and subsequent to the worldwide 
adoption of temozolomide. 
DESIGN AND SETTING: retrospective case series. 
PATIENTS AND METHODS: Charts of consecutive patients with a pathologic diagnosis of high-grade glioma 
diagnosed between January 2003 and December 2008 were retrospectively reviewed. 
RESULTS: We identified 146 adult patients, including 105 males and 41 females between 19 and 81 years of 
age (median age, 51 years), with histologically confirmed high-grade glioma. all patients underwent craniotomy. 
Eighty-two patients were treated with radiotherapy and temozolomide, of whom 42 patients received temozolo-
mide concurrent with radiation followed by adjuvant temozolomide; 40 patients received irradiation followed 
sequentially by 6 cycles of temozolomide. in 40 patients irradiation was utilized as a single modality treatment 
adjuvant to surgery. the follow-up ranged from 1 to 56 months (median, 9.4 months). the median survival for the 
whole cohort was 10.2 months. the median survival for the radiotherapy-alone group was 5.3 months and for 
combined radiotherapy/temozolomide was 14.8 months. survival was similar in both concurrent and sequential 
groups. temozolomide conferred a statistically significant survival benefit of 9 months compared with standard 
therapeutic modalities. 
CONCLUSIONS: the results compare favorably to those reported in developed nations. Current management 
of GBm in developing countries should include maximal surgical resection followed by radiotherapy/temo-
zolomide whenever medically and/or financially feasible. outcomes comparable to those obtained within the 
context of randomized trials can be expected in low-income settings if healthcare delivery is carefully planned. 
our results indicate that concurrent and sequential regimens are equally effective in these patients.
followed by adjuvant TMZ (RT/TMZ regimen) has 
been adopted as the new standard of care in most devel-
oped countries. In contrast, the management of patients 
with GBM in developing countries is still hindered by 
the paucity of clear protocols due in part to growing 
economic restraints and the lack of availability of ex-
pensive chemotherapeutic agents. As a consequence, 
growing debate is unfolding as to whether the addition 
of an expensive chemotherapeutic agent is justifiable in 
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limited-resource countries. Does the addition of TMZ 
translate into overt survival benefit in these patients? In 
this retrospective review we report the typical manage-
ment of patients with GBM in a low-income country 
highlighting the heterogeneity of treatment delivery 
and the achievable outcomes. 
PATIENTS AND METHODS
Charts of consecutive patients with a pathologic di-
agnosis of high-grade glioma diagnosed and treated 
at King Hussein Cancer Center (KHCC) between 
January 2003 and December 2008 were retrospectively 
reviewed following acquisition of institutional review 
board approval in an attempt to extract data pertaining 
to pathological characteristics, clinical status, therapeu-
tic alternatives and disease outcome. Records of imag-
ing studies were made available for this review. Patients 
≤18 years of age at the time of diagnosis were excluded 
from this case series. Pre-treatment performance status 
was evaluated according to the Karnofsky performance 
indicator (KPS) scale with 70% defined as the cut-off 
score.5 Surgical resection status was designated as par-
tial if only biopsy or partial resection was performed 
or aggressive if an attempt at resection was undertaken 
including near total, subtotal and gross total resection. 
Kaplan-Meier survival analysis was utilized to assess 
overall survival independent and dependent of various 
treatment modalities and variables. A P value ≤.05 was 
considered statistically significant. Statistical analysis 
was performed using SAS version 9.1 (SAS Institute 
Inc, Cary, NC).
RESULTS
One hundred forty five patients met the eligibility cri-
teria (Table 1). The group included 105 males and 41 
females between 19 to 81 years in age (median age, 51 
years). Seventy-five patients had KPS ≥70%. One hun-
dred and thirty patients (89%) harbored supratentorial 
tumors. Assessment of tumor size was possible in all but 
six patients and ranged from 2 to 10.5 cm. The median 
tumor size of 5.5 cm was elected as a cut-off tumor size 
for evaluation of potential prognostic variables. In 44 
patients (30%) the tumor size was <5.5 cm, while in 95 
patients (65.5%) the tumor was ≥5.5 cm. All patients 
underwent craniotomy. The extent of surgical resection 
depended on the location and size of the tumor, patient 
performance and disease extent. Sixty-seven patients 
(46%) underwent biopsy, while surgical resection was 
performed in 78 patients (54 %). Upon pathological ex-
amination and immunohistochemical confirmation by 
glial fibrillary acidic protein, GBM was found in 141 
patients. Specimens from the 4 patients who harbored 
gliosarcoma revealed evidence of mesenchymal differ-
entiation and increased deposition of reticulin in areas 
of sarcomatomous differentiation. 
Following adoption of the Stupp et al. protocol in 
2005,4 our standard approach dictated RT concurrent 
with daily TMZ at a dose of 75 mg/m2 to be followed 
by daily adjuvant TMZ at a dose of 150 mg/m2 dur-
ing days 1-5 of a 28-day cycle for six cycles initiated 
three to four weeks following completion of concur-
rent therapy. Eighty-eight patients (60.5%) received 
adjuvant TMZ, of which 82 received it in addition 
to RT (Table 2). In six patients TMZ was the sole 
adjuvant modality consequent to poor overall perfor-
mance. Patients with unfavorable prognostic vari-
Table 1. Characteristics of all patients (n=145).
Number 
of 
patients
Percent
Gender
male 104 72
female 41 28
Location Supratentorial 129 89 
infratentorial 11 7.5
multifocal 5 3.5
Size range (cm) 1.6-10.5
median (cm) 
   <5.5 cm 44 30
   ≥ 5.5 cm 95 65.5
   not assessed 6 4.5
Type of 
surgery 
biopsy 67 46
Gross total 
resection 10 6.5 
near total 
resection 5 3.5
Partial resection 27 19
Subtotal resection 36 25
Pathology Gbm 141 97
Gliosarcoma 4 3
Adjuvant 
therapy
Concomitant 
rT/TmZ 42 29
Sequential rT/TmZ 40 27.5
TmZ alone 6 4
rT alone 40 27.5
no adjuvant 
therapy 17 12
rT: radiotherapy, TmZ: temozolomide
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ables were offered sequential RT/TMZ regimen in 
the form of RT followed by adjuvant TMZ after 3-4 
weeks of rest in the form of 150 mg/m2 during days 
1-5 of a 28-day cycle for six cycles. In the remain-
ing 42 patients, concurrent RT/TMZ regimen was 
offered (Table 3). Forty patients (27.5%) received 
RT alone as they were diagnosed prior to adoption 
of TMZ (2003-2004), consequent to poor overall 
condition and/or as a result of death prior to initia-
tion of TMZ. The radiation dose ranged from 5400 
to 6000 cGy and was delivered via conventional 1.8-2 
Gy fractionation, 5 days per week for 5-6 weeks. In 
13 patients, suboptimal radiation doses ranging from 
4400 to 5000 cGy were delivered due to the dose-lim-
iting tolerance limits of neighboring normal tissues. 
Five patients died during the course of radiation and 
in 4 patients RT was withheld due to deterioration 
of overall general condition. As such, 100 patients re-
ceived RT at a dose of ≥5400 cGy and 22 patients re-
ceived doses <5400 cGy. Seventeen patients received 
neither TMZ nor RT due to poor overall condition 
or medical contraindication for treatment. The major-
ity died within 2 months.
At a median follow-up of 9.4 months (range, 1-56 
months), the median survival for the whole cohort was 
10.2 months (Figures 1, 2). The median survival for 
the RT-alone group was 5.3 months and for combined 
TMZ/RT was 14.8 months, with a median survival 
benefit of 9.4 months (P=.0009). The poor overall sur-
vival exhibited in the RT-alone group might be partially 
explained by the poor patient characteristics (Table 3). 
Survival was significantly better among patients with 
KPS ≥70%, age ≤50 years, RT dose ≥5400 cGy, among 
those who had more aggressive tumor resection and a 
supratentorial tumor location (Figure 3). Tumor size 
and gender did not confer any statistically significant 
difference in survival.
Using a stepwise Cox Hazard model, treatment 
(TMZ or TMZ/RT versus RT alone and aggressive 
surgical resection versus partial resection) and KPS 
status were the most significant factors impacting 
survival. The hazard ratio (HR) for RT as compared 
to TMZ/RT was 1.9 (95% confidence interval [CI], 
1.25 to 3.01; P=.003) and for partial as compared to 
aggressive surgical resection was 1.96 (95% CI, 1.32 to 
2.91; P=.0008). Additionally the HR for KPS <70% as 
compared to KPS ≥70% was 2.4 (95% CI, 1.6 to 3.6; 
P<.001). Surprisingly, and even though comparable in 
terms of patient demographics and tumor characteris-
tics, concurrent and sequential RT/TMZ groups dem-
onstrated similar overall survival and the unadjusted 
survival for RT/TMZ sequencing was not statistically 
Figure 1. Kaplan-meier estimate of overall survival for all patients 
with Gbm.
Table 2. The use of adjuvant rT in a cohort of patients.
Treatment 
groups Number Subgroups Number
RT alone 40
diagnosed before 2005 8
medically unfit for systemic treatment with 
TmZ 17
died before TmZ initiation 15
RT dose
  ≥54 Gy 100 rT alone 24
Sequential rT/TmZ  38
Concomitant rT/TmZ 35
 
<54 Gy 22 dose adjusted to 44-50 Gy according to the  
limiting tolerance of neighboring normal 
tissue
13
Patients did not complete rT  because of 
death 5
rT was stopped due to deterioration in the 
general condition 4
Table 3. Characteristics of patients who received concomitant and sequential TmZ 
treatment as compared with patients who received radiotherapy alone.
Concomitant 
RT/TMZ group 
(42 patients)
n (%)
Sequential RT/
TMZ group 
(40 patients)
n (%)
RT alone group 
(40 patients) 
n (%)
KPS ≥70% 26 (62) 26 (65) 12 (30)
age ≤50 22 (52) 19 (47) 7 (18)
aggressive 
resection 24 (57) 19 (48) 8 (20)
rT dose 
≥54 Gy 35 (83) 38 (95) 24 (60)
Supra-
tentorial 
location 
38 (90) 35 (87) 24 (60)
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Figure 2. Kaplan-meier estimate of overall survival for patients according to treatment 
modality.
Figure 3. Overall survival of the entire cohort according to the extent of surgical 
resection.
significant (P=.2535)
DISCUSSION
In Jordan, CNS malignancies account for 3.3% of all 
newly diagnosed malignant tumors, ranking the 8th 
most common cancer. Approximately 60% of all brain 
cancers are of astrocytic histology, of which GBM is the 
most common subtype.6 Demographically, and in con-
trast to the US SEER data, approximately two-thirds 
of cases in Jordanians occur among patients younger 
than 50 years of age, a finding possibly explained by the 
differences in age demographics of both populations.7 
Nonetheless, patient demographic characteristics in 
this case review are comparable to those in previously 
published US reports. 
The landmark phase III clinical trial conducted by 
European Organization for Research and Treatment of 
Cancer (EORTC) and the National Cancer Institute 
of Canada (NCIC) in 2004 clearly demonstrated that 
concurrent RT plus TMZ followed by six cycles of 
TMZ significantly prolonged survival, with a median 
survival benefit of 2.5 months compared to RT alone in 
patients with newly diagnosed GBM.4 In the updated 
report published in 2009, survival benefit continued to 
be statistically significant at 5 years follow-up for the 
same cohort of patients.8
In Jordan, healthcare is delivered via national, univer-
sity and private hospitals. National hospitals are funded, 
managed and operated by the Ministry of Health and 
provide near-global low-cost primary care coverage. 
University hospitals, on the other hand, deliver special-
ized tertiary care. Private hospitals deliver fee-for-service 
care. KHCC is the sole comprehensive cancer center in 
the country, treating approximately 70% of all cancer cas-
es per year. Care is delivered via a multidisciplinary ap-
proach and is heavily evidence-driven. Unfortunately, sev-
eral gaps hinder the provision of comprehensive quality 
care for GBM patients outside our institution including 
inappropriate clinical practices, insufficient implementa-
tion of evidence-based medicine and unbalanced physical 
distribution of care providers.9 Similar therapeutic varia-
tions are normally observed among developing countries. 
The impact of scarce-resource allocation is of particu-
lar importance in low-income nations. This applies to 
expensive chemotherapeutic agents such as TMZ and 
intensity modulated radiation therapy. According to the 
EORTC 26981/22981 NCI-C CE3 Intergroup Study, 
the cost of TMZ for the mean survival benefit per life 
year is €37 361.10
The median survival of our cohort of patients is con-
sistent with the established range in the literature.1,4,11 
Our review demonstrated that the addition of TMZ to 
RT is superior to RT alone, with a median improve-
ment in survival of 9.4 months. Findings in this study 
compare favorably to those obtained via the EORTC/
NCI trial with similar survival rates at 6, 12, 18 and 24 
months (Table 4, Figure 4). 
In conclusion, the addition of TMZ confers a sig-
nificant survival benefit to patients with GBM. Current 
management of GBM in developing countries should 
include maximal surgical resection followed by RT/
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Figure 4. Survival for both studies for the rT-TmZ group.
Table 4. Comparison of survival for both studies.
RT/TMZ EORTC/NCI trial(N=287)
KHCC review
(N= 82)
median survival 
(months)
14.6 
(13.2-16.8)
14.75
(12.46-19.28)
   at 6 months 86.3 85.3
  at 12 months 61.1 61.8
  at 18 months 39.4 39.6
  at 24 months 26.5 23.5
TMZ whenever medically and/or financially feasible. 
Outcomes comparable to those obtained within the 
context of randomized trials can be expected in low-in-
come settings if healthcare delivery is carefully planned. 
Our results indicate that concurrent and sequential 
RT/TMZ regimens are equally effective in these pa-
tients. We believe that a prospective randomized trial is 
warranted to confirm these unexpected findings. 
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